In 2023, India crossed 101 million people living with type 2 diabetes — officially surpassing China to become the diabetes capital of the world. The same year, a landmark Lancet projection study modelled that India is on course to have the highest number of people living with obesity of any nation on Earth by 2050. These are not projections about a distant future — they describe a crisis that is already underway in Indian cities, Indian kitchens, and Indian bodies right now. Understanding why it is happening, and at what unusual speed, is the first step to addressing it.
Key Takeaways
- India has 101 million diabetics and 136 million pre-diabetics (ICMR 2023) — the largest diabetes burden on Earth
- The thin-fat Indian phenomenon: Indians develop metabolic disease at significantly lower BMI than Western populations — metabolic risk begins at BMI 23 for Indians versus 30 for Europeans
- Indians have disproportionately high visceral fat relative to body weight — this is the dangerous fat surrounding organs, not the visible fat under skin
- Urban India is experiencing a double burden: simultaneously dealing with undernutrition in some populations and rapid-onset obesity in others
- GLP-1 drugs (Ozempic, Wegovy, Mounjaro) exist and work — but cost ₹15,000–25,000/month, placing them out of reach for the vast majority of Indians who need them most
The Numbers: How Bad Is It?
The scale of India’s metabolic disease crisis is difficult to fully absorb. Consider the data:
- Diabetes: 101 million confirmed diabetics in 2023 (ICMR-INDIAB study). India now has more diabetics than any other country, overtaking China for the first time.
- Pre-diabetes: 136 million Indians have pre-diabetes — elevated blood glucose that has not yet crossed the clinical diabetes threshold. The majority will progress to full diabetes within a decade without intervention.
- Overweight and obesity: According to NFHS-5 (2019–21), 24% of Indian adults are overweight or obese. This masks significant urban-rural and regional variation — urban India’s rates are 2–3 times higher than rural rates.
- Hypertension: 28% of Indian adults (ICMR 2023), with awareness rates below 50% — most people with high blood pressure do not know they have it.
- Projection: The 2024 Lancet study projects India will have 450 million overweight or obese people by 2050, the largest such burden any nation has ever carried.
The Thin-Fat Indian: Why BMI Misleads
One of the most important and underappreciated features of India’s obesity crisis is that it does not look like Western obesity. The “thin-fat Indian” phenomenon — first formally described by Professor C S Yajnik of the KEM Hospital Research Centre, Pune — describes a body composition pattern unique to South Asian populations that makes standard BMI-based risk assessment dangerously inadequate.
Indian people at a “normal” BMI by Western standards frequently have:
- High visceral fat: Visceral adipose tissue (fat surrounding the abdominal organs — liver, pancreas, intestines) is metabolically active in a harmful way, producing inflammatory cytokines and disrupting insulin signalling. Indians carry disproportionately more visceral fat relative to total body weight than Europeans at any given BMI.
- Low muscle mass: Indian adults, even those who appear slim, typically have lower skeletal muscle mass relative to body size than European counterparts. Low muscle mass worsens insulin resistance independently of fat mass.
- Higher insulin resistance at lower BMI: Population studies show Indians begin showing signs of insulin resistance at BMI 22–23, compared to Europeans who typically show it at BMI 27–30. This is why India’s WHO BMI cutoffs were revised — the standard international cutoffs systematically underestimate metabolic risk in Indians.
The practical implication is stark: an Indian adult at BMI 24 — classified as “normal” by standard criteria — may already have significant metabolic risk. Body fat percentage and waist circumference are more informative measures for Indian adults than BMI alone.
What Is Driving the Crisis
Five Drivers of India’s Obesity and Metabolic Crisis
Ultra-processed food explosion. Indian consumption of ultra-processed foods (instant noodles, commercial biscuits, packaged chips, carbonated beverages) has more than doubled in a decade. These products are engineered for palatability, caloric density, and addictive consumption — they displace the high-fibre traditional Indian diet that was naturally protective against metabolic disease.
Rapid sedentarisation of urban India. The shift from physical labour to desk-based and service sector work has happened at extraordinary speed in Indian cities. The average urban Indian now takes fewer than 5,000 steps per day — well below the 7,500–10,000 associated with metabolic health. This transition has happened faster than any comparable population has managed.
Sleep deprivation at scale. Urban Indian adults average 6.5 hours of sleep per night — significantly below the 7.5–8 hours associated with metabolic health. Sleep deprivation raises ghrelin (hunger hormone), reduces leptin (satiety hormone), elevates cortisol, and directly impairs insulin sensitivity. This is a population-level metabolic risk factor operating silently.
Chronic psychological stress. Economic aspiration, competitive pressure, family obligations, traffic, noise, financial uncertainty — urban India produces exceptionally high chronic stress loads. Elevated cortisol promotes central fat deposition (visceral fat accumulation) and drives insulin resistance through multiple mechanisms. Chronic stress is both a cause and an amplifier of the metabolic crisis.
Intergenerational nutritional programming. Multiple studies show that maternal undernutrition during pregnancy — still common in India — programmes the fetus for efficient fat storage and insulin resistance. A child born to an undernourished mother is metabolically predisposed to accumulate visceral fat when calorie-rich food becomes available. This is why the first generation of well-fed Indians, born to undernourished parents, has exceptionally high metabolic disease rates.
The GLP-1 Drug Access Gap
Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and the growing pipeline of GLP-1 and dual-agonist weight loss drugs represent the most effective pharmaceutical obesity treatments ever developed — producing 15–22% body weight loss in clinical trials. They work particularly well for the visceral fat and insulin resistance pattern characteristic of Indian-type obesity.
But they are essentially inaccessible to the populations who most need them in India:
- Ozempic: ₹15,000–18,000 per month in India (imported). Out of reach for 95%+ of Indians.
- Mounjaro/tirzepatide: ₹20,000–25,000 per month. Similarly inaccessible.
- Domestic manufacturers are working on biosimilar semaglutide — some Indian companies have approval for the manufacturing process, but commercial launch timelines remain unclear.
- Insurance coverage for obesity treatment in India is almost nonexistent. These are entirely out-of-pocket costs.
The cruel irony is that the patients who would benefit most — lower-income Indians with limited access to gym memberships, nutritional counselling, and whole foods — are precisely those for whom these drugs are financially unattainable.
What Every Indian Can Do Right Now
While systemic solutions require policy action, individual and family-level changes can dramatically reduce metabolic risk without expensive drugs or equipment:
- Return to traditional Indian eating patterns. The traditional Indian diet — dal, sabzi, roti (whole grain), rice in moderate portions, dahi — is metabolically protective. The problem is not Indian food; it is the replacement of traditional Indian food with ultra-processed alternatives.
- Walk more. Walking after meals (even 10 minutes) has measurable effects on post-meal blood glucose. A 20–30 minute walk after dinner is one of the most evidence-backed insulin-sensitising interventions available — free and accessible to everyone.
- Check waist circumference, not just weight. A waist measurement above 90cm in men and 80cm in women indicates elevated visceral fat risk by Indian-specific standards (lower than Western cutoffs).
- Get a basic metabolic panel annually. Fasting glucose, HbA1c, and lipid profile. These catch pre-diabetes and early metabolic dysfunction before it becomes full diabetes. Most government hospitals offer these for very low cost.
- Prioritise sleep. Seven to eight hours is not a luxury — it is metabolic medicine. Consistent sleep deprivation is as damaging to insulin sensitivity as a poor diet.
For those looking for additional metabolic support alongside diet and lifestyle changes, evidence-backed natural compounds can help improve insulin sensitivity and support healthy weight management. Check out this highly-rated metabolic health supplement on Amazon.in — a practical addition to lifestyle interventions for anyone managing their metabolic health in India.
Related: Natural Ways to Boost GLP-1
You do not need Ozempic to activate GLP-1 pathways. Several natural strategies have evidence for boosting GLP-1 and improving insulin sensitivity without a prescription. Read more: How to Lose Weight Like Ozempic — Without the Prescription
Dr. Ajit Jha’s Clinical Perspective
“I have been practising medicine in India for over two decades, and what I am seeing in my clinic over the past ten years is genuinely alarming. Patients who would previously have come to me at age 55 with their first elevated blood sugar are now coming at 40. I am seeing pre-diabetes in 28 and 30-year-olds who are not overweight by any visible measure — they are thin-fat, with normal BMI and dangerous visceral fat. The numbers from ICMR do not surprise me at all. What concerns me most is that we are dealing with a crisis that our healthcare system was simply not designed to handle at this scale. My practical message to every Indian adult, especially those in cities: get your HbA1c tested today if you have not done it in the last two years. Do not wait for symptoms — type 2 diabetes can progress silently for years before causing symptoms. Walk for 20 minutes after dinner every night. These two actions alone — knowing your number and walking regularly — will do more than any supplement or health trend for the average Indian’s metabolic future.”
— Dr. Ajit Jha, MD Medicine | IMA Lifetime Member | Editorial Board Member, International Journal of Diabetes and Endocrinology (IJDE)
Frequently Asked Questions
At what BMI should Indians be concerned about obesity-related risk?
The Indian-specific BMI thresholds are lower than international standards. The Asia-Pacific guidelines (endorsed by organisations including the Indian Council of Medical Research) recommend: BMI 23+ as overweight for Indians, and BMI 27.5+ as obese. For waist circumference, the Indian-specific cutoffs are 90cm for men and 80cm for women. Using Western BMI cutoffs (25 for overweight, 30 for obese) will systematically miss a significant proportion of metabolically at-risk Indian adults.
Will cheap generic Ozempic be available in India soon?
Several Indian pharmaceutical companies — including Sun Pharma, Dr. Reddy’s, and others — have announced biosimilar semaglutide programmes. India’s National Pharmaceutical Pricing Authority is expected to regulate pricing if approved. Some estimates suggest biosimilar semaglutide could become available at significantly lower prices (possibly ₹3,000–6,000/month) within 2–4 years if regulatory approvals proceed. The timeline is uncertain, but the direction is clear — GLP-1 drugs will become more accessible in India as the patent landscape evolves.
Is the traditional Indian diet actually protective against metabolic disease?
Yes — when eaten as traditionally composed. The problem is not Indian cuisine; it is the specific elements that have changed. Traditional Indian meals were high in dietary fibre (dal, sabzi, whole grains), included fermented foods (dahi, idli, dosa), were moderate in refined carbohydrates, and were consumed in patterns aligned with daylight hours. The ultra-processed replacement foods — maida-based snacks, packaged foods, sweetened beverages — are the primary driver of the metabolic shift, not Indian food itself.
My BMI is normal but my doctor says I have pre-diabetes. How is that possible?
This is the thin-fat Indian phenomenon. Your total body weight may be normal while your body composition — the ratio of muscle to visceral fat — is problematic. Indians frequently carry significant visceral fat (around abdominal organs) at weights that appear normal by Western standards. An HbA1c or fasting glucose test measures actual metabolic function, which is a more honest indicator of your metabolic health than BMI. If your glucose numbers are elevated, take them seriously regardless of what your BMI says.
📖 Related Articles